These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12852762)

  • 1. A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors.
    Sims PA; Wong CF; McCammon JA
    J Med Chem; 2003 Jul; 46(15):3314-25. PubMed ID: 12852762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics.
    Schoepfer J; Fretz H; Chaudhuri B; Muller L; Seeber E; Meijer L; Lozach O; Vangrevelinghe E; Furet P
    J Med Chem; 2002 Apr; 45(9):1741-7. PubMed ID: 11960485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Charge optimization of the interface between protein kinases and their ligands.
    Sims PA; Wong CF; McCammon JA
    J Comput Chem; 2004 Aug; 25(11):1416-29. PubMed ID: 15185335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
    Park H; Yeom MS; Lee S
    Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
    Zaharevitz DW; Gussio R; Leost M; Senderowicz AM; Lahusen T; Kunick C; Meijer L; Sausville EA
    Cancer Res; 1999 Jun; 59(11):2566-9. PubMed ID: 10363974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative contributions of desolvation, inter- and intramolecular interactions to binding affinity in protein kinase systems.
    Sims PA; Wong CF; Vuga D; McCammon JA; Sefton BM
    J Comput Chem; 2005 May; 26(7):668-81. PubMed ID: 15754303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
    McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
    Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol.
    de Azevedo WF; Canduri F; da Silveira NJ
    Biochem Biophys Res Commun; 2002 Apr; 293(1):566-71. PubMed ID: 12054639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.
    Kim KS; Sack JS; Tokarski JS; Qian L; Chao ST; Leith L; Kelly YF; Misra RN; Hunt JT; Kimball SD; Humphreys WG; Wautlet BS; Mulheron JG; Webster KR
    J Med Chem; 2000 Nov; 43(22):4126-34. PubMed ID: 11063609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
    Davies TG; Bentley J; Arris CE; Boyle FT; Curtin NJ; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Hardcastle IR; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Wang L; Whitfield HJ
    Nat Struct Biol; 2002 Oct; 9(10):745-9. PubMed ID: 12244298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-guided discovery of cyclin-dependent kinase inhibitors.
    Fischmann TO; Hruza A; Duca JS; Ramanathan L; Mayhood T; Windsor WT; Le HV; Guzi TJ; Dwyer MP; Paruch K; Doll RJ; Lees E; Parry D; Seghezzi W; Madison V
    Biopolymers; 2008 May; 89(5):372-9. PubMed ID: 17937404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
    De Azevedo WF; Mueller-Dieckmann HJ; Schulze-Gahmen U; Worland PJ; Sausville E; Kim SH
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2735-40. PubMed ID: 8610110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the structural basis of N2 and O6 substituted guanine derivatives as cyclin-dependent kinase 2 (CDK2) inhibitors: prediction of the binding modes and potency of the inhibitors by docking and ONIOM calculations.
    Alzate-Morales JH; Caballero J; Vergara Jague A; González Nilo FD
    J Chem Inf Model; 2009 Apr; 49(4):886-99. PubMed ID: 19323453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Informative library design as an efficient strategy to identify and optimize leads: application to cyclin-dependent kinase 2 antagonists.
    Bradley EK; Miller JL; Saiah E; Grootenhuis PD
    J Med Chem; 2003 Sep; 46(20):4360-4. PubMed ID: 13678414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-QSAR CoMFA on cyclin-dependent kinase inhibitors.
    Ducrot P; Legraverend M; Grierson DS
    J Med Chem; 2000 Nov; 43(22):4098-108. PubMed ID: 11063606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand binding affinity determined by temperature-dependent circular dichroism: cyclin-dependent kinase 2 inhibitors.
    Mayhood TW; Windsor WT
    Anal Biochem; 2005 Oct; 345(2):187-97. PubMed ID: 16140252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening.
    Kim MK; Min J; Choi BY; Lim H; Cho YH; Lee CH
    J Microbiol Biotechnol; 2007 Oct; 17(10):1712-6. PubMed ID: 18156791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imidazo[2,1 -b]thiazolylmethylene- and indolylmethylene-2-indolinones: a new class of cyclin-dependent kinase inhibitors. Design, synthesis, and CDK1/cyclin B inhibition.
    Andreani A; Cavalli A; Granaiola M; Leoni A; Locatelli A; Morigi R; Rambaldi M; Recanatini M; Garnier M; Meijer L
    Anticancer Drug Des; 2000 Dec; 15(6):447-52. PubMed ID: 11716438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.
    Otyepka M; Krystof V; Havlícek L; Siglerová V; Strnad M; Koca J
    J Med Chem; 2000 Jun; 43(13):2506-13. PubMed ID: 10891109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.